Publications by authors named "Laura B Valenzuela"
Article Synopsis
- DLL3 is found in over 70% of small cell lung cancers (SCLC), which are aggressive and have few treatment options, leading to poor patient outcomes.
- HPN328 is a new trispecific T cell-activating therapy that targets DLL3, enhances T-cell activation, and prolongs its presence in the body, showing strong tumor-killing abilities in lab and animal studies.
- Initial tests indicate HPN328 is effective and safe, with plans for a clinical trial to further evaluate its effectiveness in patients with DLL3-expressing cancers.*
The author of this article wanted to change the Acknowledgments section to: These studies were supported by an award from NIDA (R01 DA041336), as well as by the Veteran's Administration VISN 22 Mental Illness Research, Education, and Clinical Center. Receptor binding and functional data were generously.
View Article and Find Full Text PDFRationale: The lysergamide lysergic acid diethylamide (LSD) is a prototypical classical hallucinogen with remarkably high potency. LSD remains a popular recreational drug but is also becoming an important research tool for medical and neuroscience studies. Recently, several lysergamides that are close structural analogs of LSD have been sold as recreational drugs, which suggests that further studies are needed to explore the pharmacological properties of these compounds.
View Article and Find Full Text PDF